ACLX: Arcellx, Inc.
About
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
Current Value
$86.871 Year Return
Current Value
$86.871 Year Return
Key Details
Market Cap
$4.74B
P/E Ratio
-117.44
1Y Stock Return
69.19%
1Y Revenue Growth
230.33%
Dividend Yield
0.00%
Price to Book
9.8
Strategies that include ACLX
Stock's related to ACLX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 49.25% | $2.09B | -9.52% | 0.00% |
| FARO | 48.06% | $486.17M | +40.51% | 0.00% |
| PK | 47.81% | $2.95B | -0.49% | 11.79% |
| TY | 47.38% | - | - | 3.32% |
| RCKY | 47.34% | $155.86M | -17.74% | 2.95% |
| RCKT | 47.26% | $1.20B | -39.83% | 0.00% |
| CRSP | 47.05% | $4.01B | -30.49% | 0.00% |
| MHO | 46.94% | $4.24B | +50.63% | 0.00% |
| ALEC | 46.72% | $377.04M | -19.46% | 0.00% |
| NTLA | 46.49% | $1.44B | -50.35% | 0.00% |
| RCUS | 46.47% | $1.33B | +5.07% | 0.00% |
| DLX | 45.46% | $1.01B | +24.44% | 5.30% |
| VBTX | 45.33% | $1.58B | +53.68% | 2.75% |
| CVCO | 45.24% | $3.82B | +69.11% | 0.00% |
| CARS | 45.11% | $1.20B | -2.01% | 0.00% |
| GPRO | 44.98% | $179.52M | -67.23% | 0.00% |
| IIPR | 44.98% | $3.01B | +33.85% | 7.00% |
| HHH | 44.93% | $3.98B | +14.89% | 0.00% |
| WD | 44.85% | $3.61B | +30.99% | 2.42% |
| KYMR | 44.83% | $2.77B | +125.95% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QTTB | -0.02% | $354.34M | +188.64% | 0.00% |
| AMED | 0.04% | $2.95B | -3.95% | 0.00% |
| MUSA | -0.07% | $10.62B | +42.37% | 0.34% |
| MKL | -0.11% | $21.48B | +16.38% | 0.00% |
| KBR | -0.34% | $7.77B | +11.73% | 1.00% |
| SRRK | 0.36% | $2.61B | +134.91% | 0.00% |
| OMCL | 0.46% | $1.96B | +30.61% | 0.00% |
| CLLS | 0.47% | $141.30M | -30.99% | 0.00% |
| KR | -0.48% | $42.03B | +35.08% | 2.11% |
| TAL | 0.59% | $4.54B | +2.16% | 0.00% |
| PEP | -0.82% | $215.02B | -6.60% | 3.35% |
| VIRT | 0.93% | $3.17B | +110.38% | 2.60% |
| LTM | 1.01% | $8.51B | -100.00% | <0.01% |
| NHTC | 1.02% | $61.83M | +0.19% | 14.81% |
| CPB | -1.05% | $12.96B | +7.08% | 3.40% |
| PRPO | -1.10% | $9.10M | -13.65% | 0.00% |
| WM | 1.13% | $87.92B | +27.58% | 1.34% |
| LU | -1.13% | $2.01B | -33.75% | 0.00% |
| ASPS | 1.16% | $22.36M | -80.26% | 0.00% |
| FCN | 1.21% | $7.10B | -10.74% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -18.37% | $78.15B | +35.51% | 0.42% |
| HUSA | -15.93% | $16.69M | -11.56% | 0.00% |
| CYCN | -12.44% | $4.77M | -16.19% | 0.00% |
| TCTM | -12.24% | $8.10M | -42.99% | 0.00% |
| CBOE | -11.14% | $21.46B | +15.84% | 1.11% |
| BTCT | -9.66% | $42.61M | +353.33% | 0.00% |
| OXBR | -9.33% | $19.05M | +178.18% | 0.00% |
| MNR | -8.46% | $1.66B | -10.71% | 15.90% |
| RNR | -8.42% | $13.74B | +23.09% | 0.58% |
| COR | -7.84% | $47.48B | +21.20% | 0.86% |
| PULM | -6.67% | $19.83M | +202.98% | 0.00% |
| SAVA | -6.21% | $1.35B | +25.50% | 0.00% |
| DAO | -5.98% | $159.28M | +25.62% | 0.00% |
| GAN | -5.97% | $83.39M | +21.19% | 0.00% |
| STG | -5.84% | $35.67M | +7.92% | 0.00% |
| NLOP | -5.25% | $458.04M | +94.60% | 0.00% |
| PRPH | -4.84% | $18.14M | -82.61% | 0.00% |
| RELY | -4.71% | $3.96B | -7.42% | 0.00% |
| K | -4.69% | $27.77B | +52.50% | 2.79% |
| PCRX | -4.38% | $772.48M | -37.25% | 0.00% |
ETF's related to ACLX
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PTH | 61.89% | $143.31M | 0.6% |
| XBI | 61.40% | $6.58B | 0.35% |
| RSPA | 59.06% | $273.87M | 0% |
| IWC | 58.65% | $933.99M | 0.6% |
| IWO | 57.60% | $12.56B | 0.24% |
| VTWO | 57.37% | $12.38B | 0.1% |
| IWM | 57.12% | $75.73B | 0.19% |
| ISCG | 56.57% | $640.00M | 0.06% |
| VXF | 56.52% | $21.54B | 0.06% |
| SMMD | 56.50% | $1.24B | 0.15% |
| FSMD | 56.28% | $583.89M | 0.15% |
| NUSC | 56.26% | $1.27B | 0.31% |
| IBB | 56.09% | $6.66B | 0.45% |
| ESML | 55.94% | $1.90B | 0.17% |
| GSSC | 55.70% | $529.86M | 0.2% |
| VB | 55.41% | $63.63B | 0.05% |
| VBK | 55.35% | $19.31B | 0.07% |
| SMLF | 55.21% | $1.44B | 0.15% |
| GNOM | 55.21% | $70.59M | 0.5% |
| PSC | 55.10% | $702.17M | 0.38% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| JBBB | -0.06% | $1.26B | 0.49% |
| IVOL | -0.08% | $548.70M | 1.02% |
| DBO | -0.84% | $217.57M | 0.77% |
| TBIL | 1.33% | $4.38B | 0.15% |
| BILZ | 1.52% | $563.02M | 0.14% |
| DBE | 1.66% | $50.13M | 0.77% |
| USCI | 1.67% | $185.47M | 1.07% |
| IBTE | 2.10% | $1.70B | 0.07% |
| GSG | 2.18% | $914.42M | 0.75% |
| COMT | 2.34% | $829.06M | 0.48% |
| CLOI | -2.36% | $715.40M | 0.4% |
| HIGH | -2.58% | $302.78M | 0.51% |
| CCOR | 3.10% | $109.04M | 1.18% |
| SGOV | 3.34% | $27.53B | 0.09% |
| DBA | -3.49% | $755.88M | 0.93% |
| PDBC | 3.71% | $4.40B | 0.59% |
| XONE | 3.89% | $548.88M | 0.03% |
| IBDP | 4.09% | $2.11B | 0.1% |
| HDRO | -4.15% | $164.26M | 0.3% |
| KRBN | 4.28% | $242.47M | 0.85% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -40.36% | $195.31M | 0.85% |
| BTAL | -39.22% | $388.04M | 1.43% |
| TAIL | -22.38% | $67.98M | 0.59% |
| USDU | -18.91% | $201.97M | 0.5% |
| TPMN | -14.11% | $40.60M | 0.65% |
| UUP | -13.32% | $309.25M | 0.77% |
| CTA | -13.29% | $350.27M | 0.78% |
| WEAT | -12.39% | $120.27M | 0.28% |
| EQLS | -10.44% | $76.08M | 1% |
| CORN | -9.99% | $61.12M | 0.2% |
| KMLM | -9.84% | $353.87M | 0.9% |
| SOYB | -8.83% | $27.32M | 0.22% |
| MINT | -5.89% | $11.62B | 0.35% |
| XHLF | -4.78% | $874.27M | 0.03% |
| KCCA | -4.65% | $220.51M | 0.87% |
| HDRO | -4.15% | $164.26M | 0.3% |
| DBA | -3.49% | $755.88M | 0.93% |
| HIGH | -2.58% | $302.78M | 0.51% |
| CLOI | -2.36% | $715.40M | 0.4% |
| DBO | -0.84% | $217.57M | 0.77% |
News
Yahoo
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo
Arcellx ( NASDAQ:ACLX ) Third Quarter 2024 Results Key Financial Results Revenue: US$26.0m (up 74% from 3Q 2023). Net...
Yahoo
Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.
Yahoo
Arcellx (ACLX) delivered earnings and revenue surprises of 11.11% and 26.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
REDWOOD CITY, Calif., November 07, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights.
Yahoo
Morgan Stanley raised the firm’s price target on Arcellx (ACLX) to $106 from $81 and keeps an Overweight rating on the shares. The firm is increasing its view of the odds of success for anito-cel following the initial data set from Arcellx’s iMMagine-1 Phase 2 trial in relapsed/refractory multiple myeloma patients, or rrMM. The firm sees “ample market share opportunity” for anito-cel, initially in later-line patients and eventually in earlier-line patients, should the current clinical profile la
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.